sb 239063 has been researched along with Innate Inflammatory Response in 7 studies
SB 239063: structure in first source
SB-239063 : A member of the class of imidazoles carrying 4-hydroxycyclohexyl, 4-fluorophenyl and 2-methoxypyrimidin-4-yl substituents at positions 1, 4 and 5 respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Despite a reduction of inflammation, treatment with the p38 inhibitor SB 239063 does not affect cardiac remodelling and cardiac function when treatment is started 7 days after myocardial infarction." | 3.74 | Role of p38 mitogen-activated protein kinase in cardiac remodelling. ( Angermann, CE; Bauersachs, J; Behr, T; Ertl, G; Fraccarollo, D; Frantz, S; Goldberg, E; Hu, K; Strotmann, J, 2007) |
| "Besides, neuroinflammation has captured more attention in the process of HE, but the mechanism of neuroinflammation leading to HE remains unclear." | 2.52 | PET and MR imaging of neuroinflammation in hepatic encephalopathy. ( Lu, GM; Su, YY; Wu, S; Yang, GF; Zhang, LJ, 2015) |
| "In a bleomycin-induced pulmonary fibrosis model in rats, treatment with SB 239063 (2." | 1.31 | SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. ( Adams, JL; Bochnowicz, S; Griswold, DE; Hay, DW; Lee, JC; Osborn, RR; Rieman, DJ; Romanic, AM; Underwood, DC; Webb, EF, 2000) |
| " dosing regimen that provided effective plasma concentrations of 0." | 1.31 | SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia. ( Adams, JL; Badger, AM; Barone, FC; Erhardt, JA; Hunter, AJ; Irving, EA; Kassis, S; Kumar, S; Lee, JC; Legos, JJ; McVey, MJ; Nelson, AH; Ohlstein, EH; Parsons, AA; Ray, AM; Smith, BR; Ward, K; White, RF, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stinson, LF | 1 |
| Ireland, DJ | 1 |
| Kemp, MW | 1 |
| Payne, MS | 1 |
| Stock, SJ | 1 |
| Newnham, JP | 1 |
| Keelan, JA | 1 |
| Su, YY | 1 |
| Yang, GF | 1 |
| Lu, GM | 1 |
| Wu, S | 1 |
| Zhang, LJ | 1 |
| Bison, S | 1 |
| Razzoli, M | 1 |
| Arban, R | 1 |
| Michielin, F | 1 |
| Bertani, S | 1 |
| Carboni, L | 1 |
| Frantz, S | 1 |
| Behr, T | 1 |
| Hu, K | 1 |
| Fraccarollo, D | 1 |
| Strotmann, J | 1 |
| Goldberg, E | 1 |
| Ertl, G | 1 |
| Angermann, CE | 1 |
| Bauersachs, J | 1 |
| Morris, JB | 1 |
| Olzinski, AR | 1 |
| Bernard, RE | 1 |
| Aravindhan, K | 1 |
| Mirabile, RC | 1 |
| Boyce, R | 1 |
| Willette, RN | 1 |
| Jucker, BM | 1 |
| Underwood, DC | 1 |
| Osborn, RR | 1 |
| Bochnowicz, S | 1 |
| Webb, EF | 1 |
| Rieman, DJ | 1 |
| Lee, JC | 2 |
| Romanic, AM | 1 |
| Adams, JL | 2 |
| Hay, DW | 1 |
| Griswold, DE | 1 |
| Barone, FC | 1 |
| Irving, EA | 1 |
| Ray, AM | 1 |
| Kassis, S | 1 |
| Kumar, S | 1 |
| Badger, AM | 1 |
| White, RF | 1 |
| McVey, MJ | 1 |
| Legos, JJ | 1 |
| Erhardt, JA | 1 |
| Nelson, AH | 1 |
| Ohlstein, EH | 1 |
| Hunter, AJ | 1 |
| Ward, K | 1 |
| Smith, BR | 1 |
| Parsons, AA | 1 |
1 review available for sb 239063 and Innate Inflammatory Response
| Article | Year |
|---|---|
PET and MR imaging of neuroinflammation in hepatic encephalopathy.
Topics: Amino Acid Transport System X-AG; Animals; Blood-Brain Barrier; Brain; Brain Edema; Cytokines; Disea | 2015 |
6 other studies available for sb 239063 and Innate Inflammatory Response
| Article | Year |
|---|---|
Effects of cytokine-suppressive anti-inflammatory drugs on inflammatory activation in ex vivo human and ovine fetal membranes.
Topics: Acetylcysteine; Amides; Animals; Anti-Inflammatory Agents; Cell-Penetrating Peptides; Cells, Culture | 2014 |
Effect of the p38 MAPK inhibitor SB-239063 on Lipopolysaccharide-induced psychomotor retardation and peripheral biomarker alterations in rats.
Topics: Animals; Biomarkers; Hormones; Imidazoles; Inflammation; Lipopolysaccharides; Male; Motor Activity; | 2011 |
Role of p38 mitogen-activated protein kinase in cardiac remodelling.
Topics: Animals; Imidazoles; Inflammation; Male; Myocardial Infarction; p38 Mitogen-Activated Protein Kinase | 2007 |
p38 MAPK inhibition reduces aortic ultrasmall superparamagnetic iron oxide uptake in a mouse model of atherosclerosis: MRI assessment.
Topics: Angiotensin II; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Contrast Media; Enzyme Inhibitor | 2008 |
SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung.
Topics: Animals; Bleomycin; Cells, Cultured; Cytokines; Disease Models, Animal; Enzyme Inhibitors; Guinea Pi | 2000 |
SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Temperature; Brain; Cerebrovascular Circulati | 2001 |